Skip to content

DR. VERLINDEN W.

Active
Private limited company (pre-2019)founded 2016active for 10 yearsWelvaartstraat 85, 2530 Boechout, BelgiumKBO/BCE: BE 0664.867.890

From the official registers: KBO 10 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

DR. VERLINDEN W. has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €20,460 and a net result of €211,455. Equity has been shrinking by about 2.7% per year since 2018. Its solvency ranks better than 12% of 20,678 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisFollow ReportCompare
DR. VERLINDEN W.ActiveChecked score 92/100
Risk analysis ReportCompare

Overview

Official details

KBO
Status
Active since 21-10-2016 Normal situation
Legal form
Private limited company (pre-2019)
Registered office
Welvaartstraat 85, 2530 Boechout
Activity
Specialist medical practice NACE 86220and 2 others
Establishment unit
2.257.839.801 2530 Boechout, since 21-10-2016
Financial year end
31 December
Peppol
Reachable since 10-12-2025
Company details

Board and ownership

Board
  • Verlinden WimDirector · since 21-10-2016
Holdings
Shares in 1 company De Gastro Groep
Board & ownership

Financial position

92 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Annual accounts 2025
Gross margin
€292,235
▲ 4.3%
Turnover
≈ €450,000
estimated
Profit
€211,455
▲ 5.1%
Equity
€20,460
=
Total assets
€278,406
▼ 12.3%
2025 accounts filed 43 days before the deadline
Filed on 18-06-2026at the National Bank
Financials
Score breakdownraises riskEquity €20,460 (7.3% of total assets)lowers riskSector: Human health activities (NACE 86)Size: total assets €278,406Figures for financial year 2025 (filed on 18-06-2026)Show the evidence

Checked score

Score 2025
92 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 33% of micro companies in human health (NACE 86)
Every signal that counts is listed under Signals.
Financial strength · tick: 2024
Average
Solvency 32+1
equity 7.3% of total assets
Liquidity 16-9
short-term debt 92.3% · cash 13.0%
Profitability 100=
return on assets 76.0%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (24,155 companies, NACE 86, micro)
Last 24 months 11-2024: < 0.1% 12-2024: < 0.1%● unchanged vs 11-2024lowest value 01-2025: < 0.1%● unchanged vs 12-2024lowest value 02-2025: < 0.1%● unchanged vs 01-2025lowest value 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: 0.1%▲ +0.1 percentage points vs 06-2026 08-2026: 0.1%● unchanged vs 07-2026 09-2026: 0.1%● unchanged vs 08-2026highest value 10-2026: 0.1%● unchanged vs 09-2026
Credit of up to €1,500 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.51 (0.54 in 2024), below 1. Short-term debt is 92.3% and cash 13% of total assets. 92.7% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 12% of them on solvency, 2% on liquidity, 80% on profitability and 37% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Size: total assets €278,406
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
raises risk · Equity €20,460 (7.3% of total assets)
NBB · annual accounts
lowers risk · Figures for financial year 2025 (filed on 18-06-2026)
NBB · annual accounts
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 12% of 20678 sector peers (2025).
NBB · sector comparison
Position among 20678 sector peers
Solvency
better than 12%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 18-06-2026, 43 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
43 days early
2024
13 days early
2023
5 days early
2022
59 days early
2021
19 days early
2020
30 days late
2019
4 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 15 days before the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 12 July (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Key points

  • Caution: Lower solvency than 88% of companies in human healthsector median 63.0% · 20,678 companies 7.3% View
  • Positive: 8 profitable years in a rowprofit 2025: €211,455 8 years View
  • Positive: Filed on time since financial year 2021accounts within the deadline every year 5 years View

Documents

Annual accounts at the NBB

All 10 annual accounts

Acts in the Belgian Official Gazette

All publications in the Belgian Official Gazette

Articles and registers

Key facts about DR. VERLINDEN W.

What is the company number of DR. VERLINDEN W.?
The company number of DR. VERLINDEN W. is 0664.867.890. The VAT number is the same number with BE in front: BE 0664.867.890.
Where is DR. VERLINDEN W. based?
The registered office is at Welvaartstraat 85, 2530 Boechout.Company details
What does DR. VERLINDEN W. do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of DR. VERLINDEN W.?
The legal form of DR. VERLINDEN W. is Private limited company (pre-2019) (BVBA).
When was DR. VERLINDEN W. founded?
DR. VERLINDEN W. was founded on 21-10-2016.
Is DR. VERLINDEN W. still active?
Yes, DR. VERLINDEN W. is an active enterprise in the KBO register.
What is the turnover of DR. VERLINDEN W.?
The turnover in financial year 2025 is ≈ €450,000. This figure is estimated from the gross margin of €292,235 and 36 comparable companies (NACE 862). It probably lies between €410,000 and €570,000.Financials
Is DR. VERLINDEN W. profitable?
In financial year 2025, DR. VERLINDEN W. made a profit of €211,455.
Where can I find the annual accounts of DR. VERLINDEN W.?
DR. VERLINDEN W. filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of DR. VERLINDEN W. due?
DR. VERLINDEN W. must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Companies linked to DR. VERLINDEN W.

Comparable companies

These companies have the same main activity as DR. VERLINDEN W.: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €254,000 and €296,000, founded between 2016 and 2017.

CompanyTotal assetsGross margin
DR. VERLINDEN W. Boechout€278,406€292,235
Anesthesie Van Zundert Mol€284,550€315,564
CroDoc Kasterlee€295,981€314,432
LAMBRECHT NOÉMIA, OPHTALMOLOGIE Kraainem€292,969€295,811
DR. KATELIJNE VERBEKE - ANESTHESIST Gent€260,802€293,007
SPOEDCONSULT Grimbergen€265,100€318,924
Dr. Anne-Sophie Vinck Zedelgem€254,305€298,127
Full comparison

Next steps

Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure